JMP Securities Downgrades Synta Pharma. (SNTA) to Market Perform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. PLTR
6. JNJ
7. LDOS
8. HUM
9. CSCO
10. KTOS

Go back to JMP Securities Downgrades Synta Pharma. (SNTA) to Market Perform

Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer

October 20, 2015 7:30 PM EDT

Company to Host Conference Call on Wednesday, October 21 at 8:00 AM ET

LEXINGTON, Mass.--(BUSINESS WIRE)-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company has decided to terminate the Phase 3 GALAXY-2 trial of ganetespib and docetaxel in the second-line treatment of patients with advanced non-small cell lung adenocarcinoma. Based on the review of a pre-planned interim analysis, the studys Independent Data Monitoring Committee (IDMC) concluded that the addition of ganetespib to docetaxel is unlikely to demonstrate a statistically significant improvement in the primary endpoint of... More